• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An unusual complication of adenosine administration in supraventricular tachycardia.

作者信息

Chakraborty Praloy, Subramanian Anandaraja

机构信息

Department of Cardiology, Vardhaman Mahavir Medical College and Safdarjang Hospital, Delhi, India.

Department of Cardiology, Indira Gandhi Government General Hospital and Postgraduate Institute, Pondicherry, India.

出版信息

Indian Pacing Electrophysiol J. 2018 Jan-Feb;18(1):36-38. doi: 10.1016/j.ipej.2017.11.002. Epub 2017 Dec 26.

DOI:10.1016/j.ipej.2017.11.002
PMID:29287916
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5840850/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/8ff0bb185494/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/c2bb9bb98beb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/3f25e7a5f7e9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/890b40d5583a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/8ff0bb185494/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/c2bb9bb98beb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/3f25e7a5f7e9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/890b40d5583a/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32bc/5840850/8ff0bb185494/gr4.jpg

相似文献

1
An unusual complication of adenosine administration in supraventricular tachycardia.腺苷用于室上性心动过速治疗时的一种罕见并发症。
Indian Pacing Electrophysiol J. 2018 Jan-Feb;18(1):36-38. doi: 10.1016/j.ipej.2017.11.002. Epub 2017 Dec 26.
2
Adenosine: a clinical experience and comparison with verapamil for the termination of supraventricular tachycardias.腺苷：终止室上性心动过速的临床经验及与维拉帕米的比较
Prog Clin Biol Res. 1987;230:283-99.
3
Oral verapamil in paroxysmal supraventricular tachycardia recurrence control: a randomized clinical trial.口服维拉帕米控制阵发性室上性心动过速复发：一项随机临床试验。
Ther Adv Cardiovasc Dis. 2015 Feb;9(1):4-9. doi: 10.1177/1753944714553425. Epub 2014 Oct 8.
4
Safety and efficacy of central intravenous bolus administration of adenosine for termination of supraventricular tachycardia.经中心静脉推注腺苷终止室上性心动过速的安全性和有效性。
J Am Coll Cardiol. 1993 Sep;22(3):741-5. doi: 10.1016/0735-1097(93)90185-4.
5
Adenosine in the management of supraventricular tachycardia in children.腺苷在儿童室上性心动过速治疗中的应用
J Paediatr Child Health. 1998 Feb;34(1):53-6. doi: 10.1046/j.1440-1754.1998.00153.x.
6
[Terminating supraventricular tachycardia with adenosine--comparing the effectiveness of 12 mg and 18 mg].[使用腺苷终止室上性心动过速——比较12毫克和18毫克的有效性]
Dtsch Med Wochenschr. 2000 Aug 18;125(33):961-9. doi: 10.1055/s-2000-7002.
7
Adenosine in the treatment of maternal paroxysmal supraventricular tachycardia.腺苷在治疗孕妇阵发性室上性心动过速中的应用
Obstet Gynecol. 1992 Sep;80(3 Pt 2):478-80.
8
Adenosine for the treatment of supraventricular tachycardia in the ED.
Am J Emerg Med. 1994 Jul;12(4):485-8. doi: 10.1016/0735-6757(94)90069-8.
9
[A randomized, multicenter trial to compare the safety and efficacy of adenosine versus verapamil for termination of paroxysmal supraventricular tachycardia].一项比较腺苷与维拉帕米终止阵发性室上性心动过速的安全性和有效性的随机多中心试验
Zhonghua Nei Ke Za Zhi. 2003 Nov;42(11):773-6.
10
Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.腺苷治疗阵发性室上性心动过速：剂量范围及与维拉帕米的比较。安慰剂对照多中心试验评估。PSVT研究组腺苷研究
Ann Intern Med. 1990 Jul 15;113(2):104-10. doi: 10.7326/0003-4819-113-2-104.

引用本文的文献

1
Adenosine-induced ventricular fibrillation in a patient with supraventricular tachycardia.一名室上性心动过速患者发生腺苷诱发的心室颤动。
Qatar Med J. 2021 Oct 7;2021(3):52. doi: 10.5339/qmj.2021.52. eCollection 2021.
2
Incidence, clinical, electrophysiological characteristics and outcomes of patients with Wolff-Parkinson-White syndrome and atrial fibrillation.预激综合征合并心房颤动患者的发病率、临床特征、电生理特点及预后
Indian Pacing Electrophysiol J. 2020 Jan-Feb;20(1):3-7. doi: 10.1016/j.ipej.2019.12.015. Epub 2020 Jan 13.

本文引用的文献

1
Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart.腺苷诱导的心房颤动：由于人类心脏中腺苷A1受体和GIRK4亚基的异质性表达，右心房外侧存在局部折返驱动因素。
Circulation. 2016 Aug 9;134(6):486-98. doi: 10.1161/CIRCULATIONAHA.115.021165. Epub 2016 Jul 26.
2
Adenosine-induced atrial fibrillation: insights into mechanism.腺苷诱发的心房颤动：机制洞察
Circ Arrhythm Electrophysiol. 2013 Jun;6(3):e34-7. doi: 10.1161/CIRCEP.113.000480.
3
Adenosine-induced ventricular fibrillation.
腺苷诱发的心室颤动。
Indian Heart J. 2001 Mar-Apr;53(2):208-10.
4
Adenosine-induced atrial arrhythmia: a prospective analysis.腺苷诱发的房性心律失常：一项前瞻性分析。
Ann Intern Med. 1997 Sep 15;127(6):417-22. doi: 10.7326/0003-4819-127-6-199709150-00001.
5
Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia.腺苷：电生理效应及用于终止阵发性室上性心动过速的治疗用途。
Circulation. 1983 Dec;68(6):1254-63. doi: 10.1161/01.cir.68.6.1254.
6
Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.腺苷治疗阵发性室上性心动过速：剂量范围及与维拉帕米的比较。安慰剂对照多中心试验评估。PSVT研究组腺苷研究
Ann Intern Med. 1990 Jul 15;113(2):104-10. doi: 10.7326/0003-4819-113-2-104.
7
Adenosine and the treatment of supraventricular tachycardia.腺苷与室上性心动过速的治疗
Am J Med. 1992 Jun;92(6):655-64. doi: 10.1016/0002-9343(92)90784-9.
8
Ventricular fibrillation in the Wolff-Parkinson-White syndrome.预激综合征伴心室颤动
N Engl J Med. 1979 Nov 15;301(20):1080-5. doi: 10.1056/NEJM197911153012003.